B-225 Plasma GFAP and NfL as biomarkers of disease classification and differential diagnosis in optic neuritis
Abstract
To test the hypothesis that plasma levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte and neuron filaments, respectively, are clinically useful biomarkers of disease classification and differential diagnosis in optic neuritis. Levels of GFAP and NfL in plasma samples were measured in healthy controls (HCs) (n=45), patients with optic neuritis (ON) (n=79), and patients with ischemic optic neuropathy (ION) (n=25) by chemiluminescence immunoassay (CLIA). We also categorized ON patients into three subgroups based on the type of patient antibodies: AQP4-positive (n=54), MOG-positive (n=11), and AQP4 and MOG double-negative (DN) (n=14). Association of GFAP and NfL levels with clinical parameters was determined. In patients with optic neuritis, plasma GFAP levels were significantly higher in AQP4-positive patients than in patients who were double negative for AQP4 and MOG (p<0.05). GFAP levels were significantly higher in AQP4-positive optic neuritis patients than in AQP4-negative (MOG-positive as well as double antibody-negative) patients (p<0.05). NfL levels were higher in AQP4-negative optic neuritis patients compared with normal subjects (p<0.05); both GFAP and NfL levels were higher in AQP4-positive optic neuritis patients than in normal subjects (p<0.05). NfL levels were lower in patients with optic neuritis compared to those with ischemic optic neuropathy (p<0.05). NfL had good differential diagnostic efficacy between ischemic optic neuropathy and optic neuritis, with an area under the ROC curve of 0.828. Plasma GFAP can be used to differentiate between AQP4-positive and AQP4-negative optic neuritis, and plasma NfL can be used as a potential biomarker for the differential diagnosis of optic neuritis and ischemic optic neuropathy.